Recently, there has been an increase in cutting-edge technologies in cell and gene therapies being developed in academic universities. The academic institutions serve as incubators of promising technologies, with corporate sponsors entering later to provide the financial backing and drug development expertise to move the product through to regulatory approval.
The model can be an efficient method to address the gaps in rare diseases and indications with high unmet needs. However, the transition of these studies from academic institution to corporate sponsorship is not always easy or straightforward. Below are some topics to consider when coordinating the transition of your study from an academic institution to corporate sponsorship.